METTL3-mediated m6A RNA methylation promotes the anti-tumour immunity of natural killer cells
Song H, Song J, Cheng M, Zheng M, Wang T, Tian S, Flavell RA, Zhu S, Li HB, Ding C, Wei H, Sun R, Peng H, Tian Z. METTL3-mediated m6A RNA methylation promotes the anti-tumour immunity of natural killer cells. Nature Communications 2021, 12: 5522. PMID: 34535671, PMCID: PMC8448775, DOI: 10.1038/s41467-021-25803-0.Peer-Reviewed Original ResearchMeSH KeywordsAdenosineAnimalsCarcinogenesisCell Line, TumorGene DeletionHomeostasisInterleukin-15Killer Cells, NaturalLymphocytes, Tumor-InfiltratingMethylationMethyltransferasesMice, Inbred C57BLMice, KnockoutNeoplasmsProtein Tyrosine Phosphatase, Non-Receptor Type 11Proto-Oncogene Proteins c-aktRNASignal TransductionTumor MicroenvironmentConceptsAnti-tumor immunityNK cellsTumor-infiltrating NK cellsNK cell infiltrationNatural killer cellsAccelerated tumor developmentExert critical rolesImmunosurveillance functionKiller cellsIL-15Cell infiltrationTumor microenvironmentTumor developmentProtein expressionSuppressed activationM6A RNA methylationEffector moleculesExpression levelsMETTL3Cells altersImmunityM6A methylationCellsPositive correlationHomeostasisCross-talk of four types of RNA modification writers defines tumor microenvironment and pharmacogenomic landscape in colorectal cancer
Chen H, Yao J, Bao R, Dong Y, Zhang T, Du Y, Wang G, Ni D, Xun Z, Niu X, Ye Y, Li HB. Cross-talk of four types of RNA modification writers defines tumor microenvironment and pharmacogenomic landscape in colorectal cancer. Molecular Cancer 2021, 20: 29. PMID: 33557837, PMCID: PMC7869236, DOI: 10.1186/s12943-021-01322-w.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorColorectal NeoplasmsCombined Modality TherapyComputational BiologyDisease ManagementDisease SusceptibilityEpithelial-Mesenchymal TransitionGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLymphocytes, Tumor-InfiltratingPharmacogeneticsPrognosisProportional Hazards ModelsRNA Processing, Post-TranscriptionalTranscription, GeneticTranscriptomeTumor MicroenvironmentConceptsColorectal cancerConsensus molecular subtypesTumor microenvironmentRNA modification patternsTME cell-infiltrating characteristicsWorse patient overall survivalDevelopment of CRCInhibitory immune cellsPD-L1 blockadeEfficacy of immunotherapyCharacteristics of TMEPatients' overall survivalPotential clinical utilityTherapeutic liabilityOverall survivalClinical featuresClinical benefitPatient survivalImmune cellsM2 macrophagesCRC samplesImmune responseMolecular subtypesClinical utilitySurvival advantage